Kangji Medical Holdings Limited (9997.HK)
- Previous Close
7.360 - Open
7.360 - Bid 7.240 x --
- Ask 7.270 x --
- Day's Range
7.220 - 7.400 - 52 Week Range
4.910 - 8.820 - Volume
1,258,067 - Avg. Volume
4,795,272 - Market Cap (intraday)
8.77B - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
13.70 - EPS (TTM)
0.530 - Earnings Date Mar 24, 2025
- Forward Dividend & Yield 0.26 (3.55%)
- Ex-Dividend Date May 27, 2025
- 1y Target Est
10.01
Kangji Medical Holdings Limited, an investment holding company, designs, develops, manufactures, and sells minimally invasive surgical instruments and accessories in Mainland China and internationally. The company offers disposable consumables, disposable trocars, disposable electrocoagulation forceps, ultrasonic scalpels, staplers and other disposable products. It provides reusable ultrasonic scalpels soft tissue cutting and hemostatic scalpel, and laparoscopic surgical instrument. In addition, the company offers instruments, including 4K UHD fluorescence camera system, 4K-ultra resolution endovision camera system, uterin visual guidance surgical system, ultrasonic soft tissue cutting and hemostatic surgical system, cold light source, morcellator, and insufflator. Its products are used in various specialties, such as obstetrics and gynecology, urology, general surgery, and thoracic surgery. The company sells products to a network of distributors, hospitals, and other customers. The company was founded in 2004 and is based in Hangzhou, China.
www.kangjimedical.com1,007
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: 9997.HK
View MorePerformance Overview: 9997.HK
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9997.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9997.HK
View MoreValuation Measures
Market Cap
8.77B
Enterprise Value
7.44B
Trailing P/E
13.67
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.88
Price/Book (mrq)
3.11
Enterprise Value/Revenue
6.87
Enterprise Value/EBITDA
9.72
Financial Highlights
Profitability and Income Statement
Profit Margin
57.65%
Return on Assets (ttm)
9.40%
Return on Equity (ttm)
17.38%
Revenue (ttm)
1.01B
Net Income Avi to Common (ttm)
581.44M
Diluted EPS (ttm)
0.530
Balance Sheet and Cash Flow
Total Cash (mrq)
1.24B
Total Debt/Equity (mrq)
0.13%
Levered Free Cash Flow (ttm)
260.12M